MedTrace Logo

Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

NCT05124483 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2022-05-20

No results posted yet for this study

Summary

Aim: To investigate if a subcutaneous (s.c.) booster dose of 90 µg of the naked Akston AKS-452 vaccine (AKS-452X) at \>= 3 months post initial vaccination, with any of the four registered vaccines, will boost the antibody titer and immune response in human healthy volunteers 4-6 weeks after s.c. injection.

Conditions

Interventions

BIOLOGICAL

AKS-452X

subcutaneous injection of 90 µg AKS-452X

Sponsors & Collaborators

  • TRACER Europe BV

    collaborator INDUSTRY

  • PRA Health Sciences

    collaborator INDUSTRY

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • Gooitzen M van Dam, MD, PhD · University Medical Center Groningen

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-21
Primary Completion
2022-07-01
Completion
2023-02-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05124483 on ClinicalTrials.gov